Keyword: CRISPR Therapeutics
Three years after Bayer and gene-editing biotech CRISPR Therapeutics joined forces to launch and run Casebia Therapeutics.
Carmen Bozic, M.D., Vertex's new head of global medicines development and medical affairs, will take over the CMO post April 1.
Though Editas and Allergan are not the first to test a CRISPR-based medicine in humans, their treatment is the first that edits DNA within the body.
The outlay will give Vertex owenership of Exonics and expand its deal with CRISPR, setting it up to use gene editing to treat DMD and DM1.
Pooling their technologies, Editas will work on cancer treatments and BlueRock will focus on neurology, cardiology and immunology.
After a year's delay, Editas Medicine will start enrolling patients in a phase 1/2 trial of its CRISPR-based treatment for LCA10, a rare form of blindness.
The FDA lifted a clinical hold it placed on Vertex and CRISPR Therapeutics’ gene-edited stem cell therapy for sickle cell disease.
CRISPR Therapeutics is partnering with ViaCyte to develop off-the-shelf, gene-edited stem cell therapies for diabetes in a deal worth up to $25 million.
In a blow to the University of California, a federal appeals court upheld CRISPR patents held by the Broad Institute.
Inscripta aims to broaden access to CRISPR by offering new enzymes for free, and to boost R&D by outfitting scientists with a full suite of tools.